HC Wainwright Brokers Raise Earnings Estimates for ACXP

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) – Stock analysts at HC Wainwright raised their Q1 2025 earnings per share estimates for Acurx Pharmaceuticals in a report released on Wednesday, March 19th. HC Wainwright analyst E. Arce now forecasts that the company will earn ($0.14) per share for the quarter, up from their previous estimate of ($0.38). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Acurx Pharmaceuticals’ current full-year earnings is ($0.89) per share. HC Wainwright also issued estimates for Acurx Pharmaceuticals’ Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.34) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.14) EPS, FY2026 earnings at ($1.49) EPS, FY2027 earnings at ($1.56) EPS and FY2028 earnings at ($1.57) EPS.

Acurx Pharmaceuticals (NASDAQ:ACXP) last issued its quarterly earnings data on Monday, March 17th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.02.

Acurx Pharmaceuticals Stock Performance

NASDAQ ACXP opened at $0.42 on Friday. The stock has a market capitalization of $9.33 million, a P/E ratio of -0.39 and a beta of -1.71. Acurx Pharmaceuticals has a 1 year low of $0.40 and a 1 year high of $3.33. The business’s fifty day moving average is $0.69 and its two-hundred day moving average is $1.24.

Institutional Investors Weigh In On Acurx Pharmaceuticals

A hedge fund recently raised its stake in Acurx Pharmaceuticals stock. Prospect Financial Services LLC lifted its stake in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) by 11.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 329,076 shares of the company’s stock after buying an additional 34,001 shares during the period. Prospect Financial Services LLC owned about 1.93% of Acurx Pharmaceuticals worth $268,000 at the end of the most recent reporting period. 11.53% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Acurx Pharmaceuticals

In related news, CEO David P. Luci purchased 49,261 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were acquired at an average cost of $1.01 per share, with a total value of $49,753.61. Following the completion of the purchase, the chief executive officer now owns 1,097,458 shares of the company’s stock, valued at $1,108,432.58. The trade was a 4.70 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 29.60% of the company’s stock.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.